Calculating risk in glaucoma

Article

Using a risk calculator might impact ocular hypertension treatment options, concluded a study published in the December 2008 issue of the Journal of Ophthalmology.

Using a risk calculator might impact ocular hypertension treatment options, concluded a study published in the December 2008 issue of the Journal of Ophthalmology.

Michael V. Boland, MD, PhD of Johns Hopkins University, Baltimore, US and colleagues used the Ocular Hypertension Treatment Study to create two scenarios with equal risk of glaucoma development, only one of which included an estimate of glaucoma risk. The team then asked glaucoma specialists to review the scenarios and make treatment recommendations, and compared the differences in these recommendations based on whether glaucoma risk had previously been identified.

The researchers found that the presence of the glaucoma risk calculator increased the specialists' confidence and consistency in their own treatment recommendations. The physicians evaluated risk factors differently based on the presence or absence of the risk calculator.

Thus the researchers concluded that presence of a risk calculator altered treatment recommendations to the extent that specialists were more reassured about their recommendations when a risk calculator was available.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
© 2025 MJH Life Sciences

All rights reserved.